Skip navigation

Biomerieux , Inc.

Private 39 Active Jobs

Scientific and technological innovation is at the heart of bioMérieux's strategy. A world leader in the field of in vitro diagnostics for 50 years, bioMérieux designs, develops, produces, and markets diagnostic systems for medical and industrial applications. bioMérieux's solutions (reagents, instruments, software, and services) are used to determine the source of disease and contamination to improve patient health and ensure consumer safety. 

To fulfill its mission to improve public health worldwide, bioMérieux is present in more than 150 countries through 41 subsidiaries. Its world headquarters are located in the Lyon area in France. 

We are committed to creating an optimal work environment that fosters teamwork, emphasizes training and offers international career development opportunities.  

Our History

bioMérieux’s commitment to public health and expertise in biology are rooted in its unique family history. In 1897, Marcel Mérieux, a student of Louis Pasteur, founded an analysis laboratory in Lyon that would become Institut Mérieux. This marks the start of an extraordinary adventure in both biology and industry.

In 1937, his son, Dr Charles Mérieux, took up the reins of his father’s laboratory. In the 1940’s, he introduced a technique developed by the Dutch Professor Frenkel - in vitro culture – which revolutionized the manufacture of vaccines and led to the production of reagents for in vitro diagnostic testing.

In 1963, Alain Mérieux, grandson of Marcel, established the diagnostics company, bioMérieux. Today it is part of Institut Mérieux, whose companies in diagnostics, immunotherapy, food safety and nutrition, are working to meet the new challenges in public health and contribute to the medicine of tomorrow.

bioMérieux represents, first and foremost, 50 years of a family’s entrepreneurial spirit and 50 years of human adventure and scientific pioneering in the interest of public health and medicine throughout the world.

Contact Us

bioMerieux Inc.